Table 3.
Distribution of patients’ characteristics and prognosis analysis for external validation set
| Risk factor | Total Patients, n(%)(n = 94) | None Hemorrhage, n(%)(n = 84) | Hemorrhage, n(%)(n = 10) | P Value |
|---|---|---|---|---|
| Gender, n(%) | ||||
| Female | 8(8.5) | 8(9.5) | 0(0.0) | |
| Male | 86(91.5) | 76(90.5) | 10(100.0) | 0.593 |
| Age, n(%) | ||||
| < 80 | 15(16.0) | 14(16.7) | 1(10.0) | |
| ≥ 80 | 79(84.0) | 70(83.3) | 9(90.0) | 0.501 |
| BMI, n(%) | ||||
| < 18.5 | 22(25.3) | 20(25.3) | 2(25.0) | |
| 18.5–23.9 | 33(37.9) | 29(36.7) | 4(50.0) | |
| > 23.9 | 32(36.8) | 30(38.0) | 2(25.0) | 0.715 |
| Rivaroxaban dose, n(%) | ||||
| < 10 mg | 56(59.6) | 48(57.1) | 8(80.0) | |
| 10 mg | 36(38.3) | 34(40.5) | 2(20.0) | |
| > 10 mg | 2(2.1) | 2(2.4) | 0(0) | 0.368 |
| Antiplatelet drugs, n(%) | ||||
| no | 66(70.2) | 59(70.2) | 7(70.0) | |
| yes | 28(29.8) | 25(29.8) | 3(30.0) | 1.000 |
| Hypertension, n(%) | ||||
| no | 23(25.0) | 23(28.0) | 0(0.0) | |
| yes | 69(75.0) | 59(72.0) | 10(100.0) | 0.061 |
| Diabetes, n(%) | ||||
| no | 59(64.1) | 53(64.6) | 6(60.0) | |
| yes | 33(35.9) | 29(35.4) | 4(40.0) | 0.742 |
| High triglyceride, n(%) | ||||
| no | 40(42.6) | 36(42.9) | 4(40.0) | |
| yes | 54(57.4) | 48(57.1) | 6(60.0) | 1.000 |
| High cholesterol, n(%) | ||||
| no | 63(67.0) | 54(64.3) | 9(90.0) | |
| yes | 31(33.0) | 30(35.7) | 1(10.0) | 0.157 |
| LDL-cholesterol abnormal, n(%) | ||||
| no | 50(53.2) | 45(53.6) | 5(50.0) | |
| yes | 44(46.8) | 39(46.4) | 5(50.0) | 1.000 |
| Lowest_hemoglobin | ||||
| < 120 | 72(76.6) | 62(73.8) | 10(100.0) | |
| ≥ 120 | 22(23.4) | 22(26.2) | 0(0.0) | 0.110 |
| Lowest_blood_platelet | ||||
| < 100 | 3(3.2) | 3(3.6) | 0(0.0) | |
| ≥ 100 | 91(96.8) | 81(96.4) | 10(100.0) | 0.771 |
| Coronary disease, n(%) | ||||
| no | 28(30.4) | 25(30.5) | 3(30.0) | |
| yes | 64(69.6) | 57(69.5) | 7(70.0) | 1.000 |
| Heart failure, n(%) | ||||
| no | 72(78.3) | 67(81.7) | 5(50.0) | |
| yes | 20(21.7) | 15(18.3) | 5(50.0) | 0.036 |
| valvulopathy, n(%) | ||||
| no | 86(93.5) | 76(92.7) | 10(100.0) | |
| yes | 6(6.5) | 6(7.3) | 0(0.0) | 1.000 |
| PCI, n(%) | ||||
| no | 82(89.1) | 72(87.8) | 10(100.0) | |
| yes | 10(10.9) | 10(12.2) | 0(0.0) | 0.594 |
| apoplexy, n(%) | ||||
| no | 59(64.1) | 54(65.9) | 5(50.0) | |
| yes | 33(35.9) | 28(34.1) | 5(50.0) | 0.486 |
| Hemorrhage history, n(%) | ||||
| no | 82(87.2) | 76(90.5) | 6(60.0) | |
| yes | 12(12.8) | 8(9.5) | 4(40.0) | 0.022 |
| Coagulopathy, n(%) | ||||
| no | 92(97.9) | 84(100.0) | 8(80.0) | |
| yes | 2(2.1) | 0(0.0) | 2(20.0) | 0.010 |
| TT, n(%) | ||||
| < 15 | 7(8.2) | 7(9.2) | 0(0.0) | |
| 15–21 | 75(88.2) | 66(86.8) | 9(100.0) | |
| > 21 | 3(3.5) | 3(3.9) | 0(0.0) | 0.511 |
| APTT, n(%) | ||||
| < 30 | 2(2.4) | 2(2.6) | 0(0.0) | |
| 30–45 | 73(85.9) | 66(86.8) | 7(77.8) | |
| > 45 | 10(11.8) | 8(10.5) | 2(22.2) | 0.535 |
| INR, n(%) | ||||
| 0.8–1.2 | 74(87.1) | 66(86.8) | 8(88.9) | |
| > 1.2 | 11(12.9) | 10(13.2) | 1(11.1) | 1.000 |
| Ddimer, n(%) | ||||
| ≤ 0.5 | 15(17.6) | 15(19.7) | 0(0.0) | |
| > 0.5 | 70(82.4) | 61(82.3) | 9(100.0) | 0.350 |
| ALT | ||||
| ≤ 40 | 80(95.2) | 72(96.0) | 8(88.9) | |
| > 40 | 4(4.8) | 3(4.0) | 1(11.1) | 0.370 |
| AST | ||||
| ≤ 40 | 79(92.9) | 70(92.1) | 9(100.0) | |
| > 40 | 6(7.1) | 76(7.9) | 0(0.0) | 1.000 |
| BUN | ||||
| ≤ 7.5 | 48(56.5) | 45(59.2) | 3(33.3) | |
| > 7.5 | 37(43.5) | 31(40.8) | 6(66.7) | 0.169 |
| Creatinine | ||||
| ≤ 110 | 70(82.4) | 64(84.2) | 6(66.7) | |
| > 110 | 15(17.6) | 12(15.8) | 3(33.3) | 0.192 |
P value was calculated by Fisher's exact test or Pearson Chi-Square